26
|
Afolayan-Oloye O, Anderson J, Zhang P. Eosinophils Are a Useful Morphologic Marker to Scrutinize Plasma Cells in Endometrial Polyps. Am J Clin Pathol 2022. [DOI: 10.1093/ajcp/aqac126.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Introduction/Objective
Chronic endometritis is characterized by presence of plasma cells, which can be confirmed by immune-staining for CD138. Endometrial polyps can irritate endometrium and harbor some plasma cells. As eosinophils are much easier to be identified than plasma cells on hematoxylin and eosin stained sections, the goal of this study was to investigate if the identification of eosinophils in endometrial polyps was useful to alert us for looking for plasma cells more carefully.
Methods/Case Report
Twenty-eight (28) endometrial polyp cases were retrospectively selected and eosinophils and plasma cells were searched microscopically. Cases with eosinophils and/or plasma cells found per high power filed were further stained for CD138.
Results (if a Case Study enter NA)
There were 8 cases with positive eosinophils (eosinophil group) and 18 cases without eosinophils (negative group). Age from eosinophil group ranged from 32 to 54 years old and the negative group has ages ranged from 32 to 72 years old. In eosinophil group, six of eight (6/8) cases in eosinophil group was correlated with positive CD138 positive plasma cells (ranging from 2 to 24 per high power field), whereas 2/8 cases had 1 eosinophil without confirmed CD138+ plasma cells. Negative group without eosinophils had no plasma cells identified.
Conclusion
Our data indicate that eosinophils can be an easy target for the next step to scrutinize plasma cells in endometrial polyps, thus promoting an accurate evaluation of chronic endometritis.
Collapse
|
27
|
Yang Y, Muller O, Shiraishi S, Harper M, Amundson A, Wong W, McGee L, Rwigema J, Schild S, Bues M, Fatyga M, Anderson J, Patel S, Foote R, Liu W. Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis (ORN) in Head and Neck Cancer Patients Treated with Pencil-Beam-Scanning Proton Therapy (PBSPT): A Retrospective, Case-Matched Cohort Study. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
28
|
Craig T, Tachdjian R, Bernstein J, Anderson J, Nurse C, Watt M, Juethner S, Yu M. LONG-TERM EFFICACY, SAFETY, AND QUALITY OF LIFE WITH LANADELUMAB TREATMENT IN ADOLESCENTS WITH HEREDITARY ANGIOEDEMA. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
29
|
Burke J, Popp M, Anderson J, Miller J, Notter D. The impact of sire fecal egg count estimated breeding values on indicators of offspring gastrointestinal nematode infection, and relative impact of lamb estimated breeding values on sale value of ram lambs. Small Rumin Res 2022. [DOI: 10.1016/j.smallrumres.2022.106830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
30
|
Bernstein J, Anderson J, Manning M, Tachdjian R, Bajcic P, Rodino F, Wang S, Lumry W. PRELIMINARY RETROSPECTIVE ANALYSIS OF PATIENT OUTCOMES ASSOCIATED WITH SUBCUTANEOUS C1INH PROPHYLAXIS FOR HEREDITARY ANGIOEDEMA. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
31
|
Hunter D, Anderson J, Campbell R, Mullan A, Homme J. 288 Relationship Between Socio-Economic Background of International Medical Graduates and Residency Match Results. Ann Emerg Med 2022. [DOI: 10.1016/j.annemergmed.2022.08.315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Anderson J, Brittney D, Giang G, Smith A, Lee C, Parker K, Searcy H, Benner K, Limdi N, Guimbellot J. 263 Pharmacogenomics in people with cystic fibrosis: A personalized medicine approach. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00953-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
33
|
Hatch J, Albrecht J, Presley C, Anderson J, Hamp A, Anderson J, Rundle C, Laughter M, Dellavalle R. 370 An analysis of androgenetic alopecia treatment content on Instagram and TikTok. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Abud AA, Abi B, Acciarri R, Acero MA, Adames MR, Adamov G, Adamowski M, Adams D, Adinolfi M, Aduszkiewicz A, Aguilar J, Ahmad Z, Ahmed J, Aimard B, Ali-Mohammadzadeh B, Alion T, Allison K, Monsalve SA, AlRashed M, Alt C, Alton A, Alvarez R, Amedo P, Anderson J, Andreopoulos C, Andreotti M, Andrews M, Andrianala F, Andringa S, Anfimov N, Ankowski A, Antoniassi M, Antonova M, Antoshkin A, Antusch S, Aranda-Fernandez A, Arellano L, Arnold LO, Arroyave MA, Asaadi J, Asquith L, Aurisano A, Aushev V, Autiero D, Lara VA, Ayala-Torres M, Azfar F, Back A, Back H, Back JJ, Backhouse C, Bagaturia I, Bagby L, Balashov N, Balasubramanian S, Baldi P, Baller B, Bambah B, Barao F, Barenboim G, Alzas PB, Barker G, Barkhouse W, Barnes C, Barr G, Monarca JB, Barros A, Barros N, Barrow JL, Basharina-Freshville A, Bashyal A, Basque V, Batchelor C, Chagas EBD, Battat JBR, Battisti F, Bay F, Bazetto MCQ, Alba JLLB, Beacom JF, Bechetoille E, Behera B, Beigbeder C, Bellantoni L, Bellettini G, Bellini V, Beltramello O, Benekos N, Montiel CB, Neves FB, Berger J, Berkman S, Bernardini P, Berner RM, Bersani A, Bertolucci S, Betancourt M, Rodríguez AB, Bevan A, Bezawada Y, Bezerra TJC, Bhardwaj A, Bhatnagar V, Bhattacharjee M, Bhattarai D, Bhuller S, Bhuyan B, Biagi S, Bian J, Biassoni M, Biery K, Bilki B, Bishai M, Bitadze A, Blake A, Blaszczyk F, Blazey GC, Blucher E, Boissevain J, Bolognesi S, Bolton T, Bomben L, Bonesini M, Bongrand M, Bonilla-Diaz C, Bonini F, Booth A, Boran F, Bordoni S, Borkum A, Bostan N, Bour P, Bourgeois C, Boyden D, Bracinik J, Braga D, Brailsford D, Branca A, Brandt A, Bremer J, Breton D, Brew C, Brice SJ, Brizzolari C, Bromberg C, Brooke J, Bross A, Brunetti G, Brunetti M, Buchanan N, Budd H, Butorov I, Cagnoli I, Cai T, Caiulo D, Calabrese R, Calafiura P, Calcutt J, Calin M, Calvez S, Calvo E, Caminata A, Campanelli M, Caratelli D, Carber D, Carceller JC, Carini G, Carlus B, Carneiro MF, Carniti P, Terrazas IC, Carranza H, Carroll T, Forero JFC, Castillo A, Castromonte C, Catano-Mur E, Cattadori C, Cavalier F, Cavallaro G, Cavanna F, Centro S, Cerati G, Cervelli A, Villanueva AC, Chalifour M, Chappell A, Chardonnet E, Charitonidis N, Chatterjee A, Chattopadhyay S, Neyra MSSC, Chen H, Chen M, Chen Y, Chen Z, Chen-Wishart Z, Cheon Y, Cherdack D, Chi C, Childress S, Chirco R, Chiriacescu A, Chisnall G, Cho K, Choate S, Chokheli D, Chong PS, Christensen A, Christian D, Christodoulou G, Chukanov A, Chung M, Church E, Cicero V, Clarke P, Cline G, Coan TE, Cocco AG, Coelho JAB, Colton N, Conley E, Conley R, Conrad J, Convery M, Copello S, Cova P, Cremaldi L, Cremonesi L, Crespo-Anadón JI, Crisler M, Cristaldo E, Crnkovic J, Cross R, Cudd A, Cuesta C, Cui Y, Cussans D, Dalager O, da Motta H, Da Silva Peres L, David C, David Q, Davies GS, Davini S, Dawson J, De K, De S, Debbins P, De Bonis I, Decowski MP, De Gouvêa A, De Holanda PC, De Icaza Astiz IL, Deisting A, De Jong P, Delbart A, Delepine D, Delgado M, Dell’Acqua A, Delmonte N, De Lurgio P, de Mello Neto JRT, DeMuth DM, Dennis S, Densham C, Deptuch GW, De Roeck A, De Romeri V, De Souza G, Devi R, Dharmapalan R, Dias M, Diaz F, Díaz JS, Domizio SD, Giulio LD, Ding P, Noto LD, Dirkx G, Distefano C, Diurba R, Diwan M, Djurcic Z, Doering D, Dolan S, Dolek F, Dolinski M, Domine L, Donon Y, Douglas D, Douillet D, Dragone A, Drake G, Drielsma F, Duarte L, Duchesneau D, Duffy K, Dunne P, Dutta B, Duyang H, Dvornikov O, Dwyer D, Dyshkant A, Eads M, Earle A, Edmunds D, Eisch J, Emberger L, Emery S, Englezos P, Ereditato A, Erjavec T, Escobar C, Eurin G, Evans JJ, Ewart E, Ezeribe AC, Fahey K, Falcone A, Fani’ M, Farnese C, Farzan Y, Fedoseev D, Felix J, Feng Y, Fernandez-Martinez E, Menendez PF, Morales MF, Ferraro F, Fields L, Filip P, Filthaut F, Fiorini M, Fischer V, Fitzpatrick RS, Flanagan W, Fleming B, Flight R, Fogarty S, Foreman W, Fowler J, Fox W, Franc J, Francis K, Franco D, Freeman J, Freestone J, Fried J, Friedland A, Robayo FF, Fuess S, Furic IK, Furman K, Furmanski AP, Gabrielli A, Gago A, Gallagher H, Gallas A, Gallego-Ros A, Gallice N, Galymov V, Gamberini E, Gamble T, Ganacim F, Gandhi R, Gandrajula R, Gao F, Gao S, Garcia-Gamez D, García-Peris MÁ, Gardiner S, Gastler D, Gauvreau J, Ge G, Geffroy N, Gelli B, Gendotti A, Gent S, Ghorbani-Moghaddam Z, Giammaria P, Giammaria T, Giangiacomi N, Gibin D, Gil-Botella I, Gilligan S, Girerd C, Giri AK, Gnani D, Gogota O, Gold M, Gollapinni S, Gollwitzer K, Gomes RA, Bermeo LVG, Fajardo LSG, Gonnella F, Gonzalez-Diaz D, Gonzalez-Lopez M, Goodman MC, Goodwin O, Goswami S, Gotti C, Goudzovski E, Grace C, Gran R, Granados E, Granger P, Grant A, Grant C, Gratieri D, Green P, Greenler L, Greer J, Grenard J, Griffith WC, Groh M, Grudzinski J, Grzelak K, Gu W, Guardincerri E, Guarino V, Guarise M, Guenette R, Guerard E, Guerzoni M, Guffanti D, Guglielmi A, Guo B, Gupta A, Gupta V, Guthikonda KK, Gutierrez R, Guzowski P, Guzzo MM, Gwon S, Ha C, Haaf K, Habig A, Hadavand H, Haenni R, Hahn A, Haiston J, Hamacher-Baumann P, Hamernik T, Hamilton P, Han J, Harris DA, Hartnell J, Hartnett T, Harton J, Hasegawa T, Hasnip C, Hatcher R, Hatfield KW, Hatzikoutelis A, Hayes C, Hayrapetyan K, Hays J, Hazen E, He M, Heavey A, Heeger KM, Heise J, Henry S, Morquecho MAH, Herner K, Hewes J, Hilgenberg C, Hill T, Hillier SJ, Himmel A, Hinkle E, Hirsch LR, Ho J, Hoff J, Holin A, Hoppe E, Horton-Smith GA, Hostert M, Hourlier A, Howard B, Howell R, Hoyos J, Hristova I, Hronek MS, Huang J, Hulcher Z, Iles G, Ilic N, Iliescu AM, Illingworth R, Ingratta G, Ioannisian A, Irwin B, Isenhower L, Itay R, Jackson CM, Jain V, James E, Jang W, Jargowsky B, Jediny F, Jena D, Jeong YS, Jesús-Valls C, Ji X, Jiang L, Jiménez S, Jipa A, Johnson R, Johnson W, Johnston N, Jones B, Jones S, Judah M, Jung CK, Junk T, Jwa Y, Kabirnezhad M, Kaboth A, Kadenko I, Kakorin I, Kalitkina A, Kalra D, Kamiya F, Kaneshige N, Kaplan DM, Karagiorgi G, Karaman G, Karcher A, Karolak M, Karyotakis Y, Kasai S, Kasetti SP, Kashur L, Kazaryan N, Kearns E, Keener P, Kelly KJ, Kemp E, Kemularia O, Ketchum W, Kettell SH, Khabibullin M, Khotjantsev A, Khvedelidze A, Kim D, King B, Kirby B, Kirby M, Klein J, Klustova A, Kobilarcik T, Koehler K, Koerner LW, Koh DH, Kohn S, Koller PP, Kolupaeva L, Korablev D, Kordosky M, Kosc T, Kose U, Kostelecký VA, Kothekar K, Kralik R, Kreczko L, Krennrich F, Kreslo I, Kropp W, Kroupova T, Kubota S, Kudenko Y, Kudryavtsev VA, Kulagin S, Kumar J, Kumar P, Kunze P, Kurita N, Kuruppu C, Kus V, Kutter T, Kvasnicka J, Kwak D, Lambert A, Land B, Lane CE, Lang K, Langford T, Langstaff M, Larkin J, Lasorak P, Last D, Laundrie A, Laurenti G, Lawrence A, Lazanu I, LaZur R, Lazzaroni M, Le T, Leardini S, Learned J, LeBrun P, LeCompte T, Lee C, Lee SY, Miotto GL, Lehnert R, de Oliveira MAL, Leitner M, Lepin LM, Li SW, Li Y, Liao H, Lin CS, Lin Q, Lin S, Lineros RA, Ling J, Lister A, Littlejohn BR, Liu J, Liu Y, Lockwitz S, Loew T, Lokajicek M, Lomidze I, Long K, Lord T, LoSecco JM, Louis WC, Lu XG, Luk KB, Lunday B, Luo X, Luppi E, Lux T, Luzio VP, Maalmi J, MacFarlane D, Machado AA, Machado P, Macias CT, Macier JR, Maddalena A, Madera A, Madigan P, Magill S, Mahn K, Maio A, Major A, Maloney JA, Mandrioli G, Mandujano RC, Maneira J, Manenti L, Manly S, Mann A, Manolopoulos K, Plata MM, Manyam VN, Manzanillas L, Marchan M, Marchionni A, Marciano W, Marfatia D, Mariani C, Maricic J, Marie R, Marinho F, Marino AD, Marsden D, Marshak M, Marshall C, Marshall J, Marteau J, Martín-Albo J, Martinez N, Caicedo DAM, Miravé PM, Martynenko S, Mascagna V, Mason K, Mastbaum A, Matichard F, Matsuno S, Matthews J, Mauger C, Mauri N, Mavrokoridis K, Mawby I, Mazza R, Mazzacane A, Mazzucato E, McAskill T, McCluskey E, McConkey N, McFarland KS, McGrew C, McNab A, Mefodiev A, Mehta P, Melas P, Mena O, Mendez H, Mendez P, Méndez DP, Menegolli A, Meng G, Messier MD, Metcalf W, Mettler T, Mewes M, Meyer H, Miao T, Michna G, Miedema T, Mikola V, Milincic R, Miller G, Miller W, Mills J, Mineev O, Minotti A, Miranda OG, Miryala S, Mishra CS, Mishra SR, Mislivec A, Mitchell M, Mladenov D, Mocioiu I, Moffat K, Moggi N, Mohanta R, Mohayai TA, Mokhov N, Molina J, Bueno LM, Montagna E, Montanari A, Montanari C, Montanari D, Zetina LMM, Moon SH, Mooney M, Moor AF, Moreno D, Moretti D, Morris C, Mossey C, Mote M, Motuk E, Moura CA, Mousseau J, Mouster G, Mu W, Mualem L, Mueller J, Muether M, Mufson S, Muheim F, Muir A, Mulhearn M, Munford D, Muramatsu H, Murphy S, Musser J, Nachtman J, Nagu S, Nalbandyan M, Nandakumar R, Naples D, Narita S, Nath A, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Negishi K, Nelson JK, Nesbit J, Nessi M, Newbold D, Newcomer M, Newton H, Nichol R, Nicolas-Arnaldos F, Nikolica A, Niner E, Nishimura K, Norman A, Norrick A, Northrop R, Novella P, Nowak JA, Oberling M, Ochoa-Ricoux J, Olivier A, Olshevskiy A, Onel Y, Onishchuk Y, Ott J, Pagani L, Palacio G, Palamara O, Palestini S, Paley JM, Pallavicini M, Palomares C, Vazquez WP, Pantic E, Paolone V, Papadimitriou V, Papaleo R, Papanestis A, Paramesvaran S, Parke S, Parozzi E, Parsa Z, Parvu M, Pascoli S, Pasqualini L, Pasternak J, Pater J, Patrick C, Patrizii L, Patterson RB, Patton SJ, Patzak T, Paudel A, Paulos B, Paulucci L, Pavlovic Z, Pawloski G, Payne D, Pec V, Peeters SJM, Perez AP, Pennacchio E, Penzo A, Peres OLG, Perry J, Pershey D, Pessina G, Petrillo G, Petta C, Petti R, Pia V, Piastra F, Pickering L, Pietropaolo F, Pimentel VL, Pinaroli G, Plows K, Plunkett R, Poling R, Pompa F, Pons X, Poonthottathil N, Poppi F, Pordes S, Porter J, Potekhin M, Potenza R, Potukuchi BVKS, Pozimski J, Pozzato M, Prakash S, Prakash T, Prest M, Prince S, Psihas F, Pugnere D, Qian X, Raaf JL, Radeka V, Rademacker J, Radics B, Rafique A, Raguzin E, Rai M, Rajaoalisoa M, Rakhno I, Rakotonandrasana A, Rakotondravohitra L, Rameika R, Delgado MAR, Ramson B, Rappoldi A, Raselli G, Ratoff P, Raut S, Razakamiandra RF, Rea EM, Real JS, Rebel B, Rechenmacher R, Reggiani-Guzzo M, Reichenbacher J, Reitzner SD, Sfar HR, Renshaw A, Rescia S, Resnati F, Ribas M, Riboldi S, Riccio C, Riccobene G, Rice LCJ, Ricol JS, Rigamonti A, Rigaut Y, Rincón EV, Ritchie-Yates H, Rivera D, Robert A, Rochester L, Roda M, Rodrigues P, Alonso MJR, Bonilla ER, Rondon JR, Rosauro-Alcaraz S, Rosenberg M, Rosier P, Roskovec B, Rossella M, Rossi M, Rout J, Roy P, Rubbia A, Rubbia C, Russell B, Ruterbories D, Rybnikov A, Saa-Hernandez A, Saakyan R, Sacerdoti S, Safford T, Sahu N, Sakashita K, Sala P, Samios N, Samoylov O, Sanchez MC, Sandberg V, Sanders DA, Sankey D, Santana S, Santos-Maldonado M, Saoulidou N, Sapienza P, Sarasty C, Sarcevic I, Savage G, Savinov V, Scaramelli A, Scarff A, Scarpelli A, Schefke T, Schellman H, Schifano S, Schlabach P, Schmitz D, Schneider AW, Scholberg K, Schukraft A, Segreto E, Selyunin A, Senise CR, Sensenig J, Sergi A, Sgalaberna D, Shaevitz MH, Shafaq S, Shaker F, Shamma M, Sharankova R, Sharma HR, Sharma R, Sharma RK, Shaw T, Shchablo K, Shepherd-Themistocleous C, Sheshukov A, Shin S, Shoemaker I, Shooltz D, Shrock R, Siegel H, Simard L, Sinclair J, Sinev G, Singh J, Singh J, Singh L, Singh P, Singh V, Sipos R, Sippach FW, Sirri G, Sitraka A, Siyeon K, Skarpaas K, Smith A, Smith E, Smith P, Smolik J, Smy M, Snider E, Snopok P, Snowden-Ifft D, Nunes MS, Sobel H, Soderberg M, Sokolov S, Salinas CJS, Söldner-Rembold S, Soleti SR, Solomey N, Solovov V, Sondheim WE, Sorel M, Sotnikov A, Soto-Oton J, Ugaldi FAS, Sousa A, Soustruznik K, Spagliardi F, Spanu M, Spitz J, Spooner NJC, Spurgeon K, Stancari M, Stanco L, Stanford C, Stein R, Steiner HM, Lisbôa AFS, Stewart J, Stillwell B, Stock J, Stocker F, Stokes T, Strait M, Strauss T, Strigari L, Stuart A, Suarez JG, Sunción JMS, Sullivan H, Summers D, Surdo A, Susic V, Suter L, Sutera CM, Svoboda R, Szczerbinska B, Szelc AM, Tanaka H, Tang S, Tapia A, Oregui BT, Tapper A, Tariq S, Tarpara E, Tata N, Tatar E, Tayloe R, Teklu AM, Tennessen P, Tenti M, Terao K, Ternes CA, Terranova F, Testera G, Thakore T, Thea A, Thompson JL, Thorn C, Timm SC, Tishchenko V, Tomassetti L, Tonazzo A, Torbunov D, Torti M, Tortola M, Tortorici F, Tosi N, Totani D, Toups M, Touramanis C, Travaglini R, Trevor J, Trilov S, Trzaska WH, Tsai Y, Tsai YT, Tsamalaidze Z, Tsang KV, Tsverava N, Tufanli S, Tull C, Tyley E, Tzanov M, Uboldi L, Uchida MA, Urheim J, Usher T, Uzunyan S, Vagins MR, Vahle P, Valder S, Valdiviesso GDA, Valencia E, Valentim R, Vallari Z, Vallazza E, Valle JWF, Vallecorsa S, Berg RV, de Water RGV, Forero DV, Vannerom D, Varanini F, Oliva DV, Varner G, Vasel J, Vasina S, Vasseur G, Vaughan N, Vaziri K, Ventura S, Verdugo A, Vergani S, Vermeulen MA, Verzocchi M, Vicenzi M, de Souza HV, Vignoli C, Vilela C, Viren B, Vrba T, Wachala T, Waldron AV, Wallbank M, Wallis C, Wang H, Wang J, Wang L, Wang MHLS, Wang X, Wang Y, Wang Y, Warburton K, Warner D, Wascko MO, Waters D, Watson A, Wawrowska K, Weatherly P, Weber A, Weber M, Wei H, Weinstein A, Wenman D, Wetstein M, White A, Whitehead LH, Whittington D, Wilking MJ, Wilkinson A, Wilkinson C, Williams Z, Wilson F, Wilson RJ, Wisniewski W, Wolcott J, Wongjirad T, Wood A, Wood K, Worcester E, Worcester M, Wresilo K, Wret C, Wu W, Wu W, Xiao Y, Xie F, Yaeggy B, Yandel E, Yang G, Yang K, Yang T, Yankelevich A, Yershov N, Yonehara K, Yoon YS, Young T, Yu B, Yu H, Yu H, Yu J, Yu Y, Yuan W, Zaki R, Zalesak J, Zambelli L, Zamorano B, Zani A, Zazueta L, Zeller GP, Zennamo J, Zeug K, Zhang C, Zhang S, Zhang Y, Zhao M, Zhivun E, Zhu G, Zimmerman ED, Zucchelli S, Zuklin J, Zutshi V, Zwaska R. Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2022; 82:618. [PMID: 35859696 PMCID: PMC9288420 DOI: 10.1140/epjc/s10052-022-10549-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 06/24/2022] [Indexed: 06/15/2023]
Abstract
DUNE is a dual-site experiment for long-baseline neutrino oscillation studies, neutrino astrophysics and nucleon decay searches. ProtoDUNE Dual Phase (DP) is a 6 × 6 × 6 m 3 liquid argon time-projection-chamber (LArTPC) that recorded cosmic-muon data at the CERN Neutrino Platform in 2019-2020 as a prototype of the DUNE Far Detector. Charged particles propagating through the LArTPC produce ionization and scintillation light. The scintillation light signal in these detectors can provide the trigger for non-beam events. In addition, it adds precise timing capabilities and improves the calorimetry measurements. In ProtoDUNE-DP, scintillation and electroluminescence light produced by cosmic muons in the LArTPC is collected by photomultiplier tubes placed up to 7 m away from the ionizing track. In this paper, the ProtoDUNE-DP photon detection system performance is evaluated with a particular focus on the different wavelength shifters, such as PEN and TPB, and the use of Xe-doped LAr, considering its future use in giant LArTPCs. The scintillation light production and propagation processes are analyzed and a comparison of simulation to data is performed, improving understanding of the liquid argon properties.
Collapse
|
35
|
Anderson J, Lévesque N, Caron F, Beckett P, Spiers GA. A review on the use of lichens as a biomonitoring tool for environmental radioactivity. JOURNAL OF ENVIRONMENTAL RADIOACTIVITY 2022; 243:106797. [PMID: 34968948 DOI: 10.1016/j.jenvrad.2021.106797] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 12/10/2021] [Accepted: 12/11/2021] [Indexed: 06/14/2023]
Abstract
Lichens have been widely used as a biomonitoring tool to record the distribution and concentration of airborne radioactivity and pollutants such as metals. There are limitations, however: although pollutants can be preserved in lichen tissues for long periods of time, not all radioactive and inert elements behave similarly. The chemical species of elements at the source, once captured, and the mode of storage within lichens play a role in this biomonitoring tool. Lichens are a symbiotic association of an algal or cyanobacterial partner (photobiont) with a fungal host (mycobiont). Lichens grow independently of the host substrates, including rocks, soils, trees and human-made structures. Lacking a root system, lichen nutrient or contaminant uptake is mostly through direct atmospheric inputs, mainly as wet and dry deposition. As lichens grow in a large variety of environments and are resilient in harsh climates, they are adapted to capture and retain nutrients from airborne sources. The context of this review partially relates to future deployment of small modular reactors (SMRs) and mining in remote areas of Canada. SMRs have been identified as a future source of energy (electricity and heat) for remote off-grid mines, potentially replacing diesel fuel generation facilities. For licensing purposes, SMR deployment and mine development requires capabilities to monitor background contaminants (natural radioactivity and metals) before, during and after deployment, including for decommissioning and removal. Key aspects reviewed herein include: (1) how lichens have been used in the past to monitor radioactivity; (2) radiocontaminants capture and storage in lichens; (3) longevity of radiocontaminant storage in lichen tissues; and (4) limitations of lichens use for monitoring radiocontaminants and selected metals.
Collapse
|
36
|
Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, Martinez‐Saguer I, Zanichelli A, Hao J, Inhaber N, Yu M, Riedl MA, Hébert J, Ritchie B, Sussman G, Yang W, Aygören‐Pürsün E, Magerl M, Martinez‐Saguer I, Staubach P, Cicardi M, Shennak M, Zaragoza‐Urdaz R, Kiani‐Alikhan S, Anderson J, Banerji A, Baptist A, Bernstein J, Busse P, Craig T, Davis‐Lorton M, Gierer S, Gower R, Harris D, Jacobs J, Johnston D, Li H, Lockey R, Lugar P, Lumry W, Manning M, McNeil D, Melamed I, Otto W, Rehman S, Riedl M, Schwartz L, Shapiro R, Sher E, Smith A, Soteres D, Tachdjian R, Wedner H, Weinstein M, Zafra H. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy 2022; 77:979-990. [PMID: 34287942 PMCID: PMC9292251 DOI: 10.1111/all.15011] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 06/06/2021] [Accepted: 06/28/2021] [Indexed: 02/06/2023]
Abstract
Background The aim was to evaluate long‐term effectiveness and safety of lanadelumab in patients ≥12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596). Methods Rollover patients completing the HELP Study and continuing into HELP OLE received one lanadelumab 300 mg dose until first attack (dose‐and‐wait period), then 300 mg q2wks (regular dosing stage). Nonrollovers (newly enrolled) received lanadelumab 300 mg q2wks from day 0. Baseline attack rate for rollovers: ≥1 attack/4 weeks (based on run‐in period attack rate during HELP Study); for nonrollovers: historical attack rate ≥1 attack/12 weeks. The planned treatment period was 33 months. Results 212 patients participated (109 rollovers, 103 nonrollovers); 81.6% completed ≥30 months on study (mean [SD], 29.6 [8.2] months). Lanadelumab markedly reduced mean HAE attack rate (reduction vs baseline: 87.4% overall). Patients were attack free for a mean of 97.7% of days during treatment; 81.8% and 68.9% of patients were attack free for ≥6 and ≥12 months, respectively. Angioedema Quality‐of‐Life total and domain scores improved from day 0 to end of study. Treatment‐emergent adverse events (TEAEs) (excluding HAE attacks) were reported by 97.2% of patients; most commonly injection site pain (47.2%) and viral upper respiratory tract infection (42.0%). Treatment‐related TEAEs were reported by 54.7% of patients. Most injection site reactions resolved within 1 hour (70.2%) or 1 day (92.6%). Six (2.8%) patients discontinued due to TEAEs. No treatment‐related serious TEAEs or deaths were reported. Eleven treatment‐related TEAEs of special interest were reported by seven (3.3%) patients. Conclusion Lanadelumab demonstrated sustained efficacy and acceptable tolerability with long‐term use in HAE patients.
Collapse
|
37
|
Taghiakbari M, Pohl H, Djinbachian R, Anderson J, Metellus D, Barkun AN, Bouin M, von Renteln D. A107 WHAT SIZE CUT-OFF LEVEL SHOULD BE USED TO IMPLEMENT OPTICAL POLYP DIAGNOSIS? J Can Assoc Gastroenterol 2022. [PMCID: PMC8859299 DOI: 10.1093/jcag/gwab049.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The risk of advanced pathology and potential mismanagement increases with polyp size while performing optical diagnosis. We hypothesized that a lower polyp size cut-off (e.g., 1–3 mm) would be associated with a lower risk of misclassifying advanced neoplasia or even cancer when using optical diagnosis.
Aims
This study aimed to evaluate the proportion of patients undergoing inadequate surveillance intervals associated with different size cut-offs when using optical diagnosis.
Methods
In a post-hoc analysis of three prospective studies, the use of optical diagnosis was evaluated for three polyp size groups: 1–3, 1–5, and 1–10 mm. The primary outcome was the proportion of patients in which advanced adenomas were found and optical diagnosis resulted in delayed surveillance in each group. Secondary outcomes included agreements between surveillance intervals based on high-confidence optical diagnosis and pathology outcomes, reduction in histopathological examinations, and proportion of patients who could receive an immediate surveillance recommendation.
Results
We included 3374 patients (7291 polyps ≤10 mm) undergoing complete colonoscopies (median age 66.0 years, 75.2% male, 29.6% for screening). Among polyp sized 1–3 mm, 1–5 mm, and 1–10 mm, 0.5%, 0.6%, and 1.2% of polyps, respectively, were found to have advanced pathology ( P <.0001). The percentage of patients with advanced adenomas and either 2- or 7- year delayed surveillance intervals (n=79) was 3.8%, 15.2%, and 25.3% for size cut-offs of 1–3, 1–5, and 1–10 mm polyps, respectively ( P<.0001). Surveillance interval agreements between pathology and high-confidence optical diagnosis for the three groups were 97.2%, 95.5%, and 94.2%, respectively. In the cohort of patients in which patients with normal colonoscopy, polyps >10 mm, and poor bowel preparation were excluded, the surveillance interval agreements between pathology and high-confidence optical diagnosis for the three groups were 96.2%, 93.6%, and 92.1%, respectively. Total reduction in pathology examinations for the three groups were 33.5%, 62.3%, and 78.2%, respectively. Furthermore, optical diagnosis could have allowed 41.0%, 58.2%, and 73.3% of patients, respectively, to be given immediate surveillance interval recommendations.
Conclusions
This study showed that limiting optical diagnosis to polyps 1–3 mm resulted in an excellent safety profile with a very low risk for inappropriate management of advanced adenomas, which makes routine clinical implementation of the “resect and discard” strategy feasible. Implementing a 3 mm cut-off could be a starting point for endoscopists to feel comfortable with the “resect and discard” strategy, with the potential of implementing a 5 mm cut-off, once optical diagnosis becomes more popular, and endoscopists become more comfortable with its use.
Funding Agencies
NoneNA
Collapse
|
38
|
Merrick G, Figol A, Anderson J, Lin RJ. Outcomes of Gender Affirming Voice Training: A Comparison of Hybrid and Individual Training Modules. JOURNAL OF SPEECH, LANGUAGE, AND HEARING RESEARCH : JSLHR 2022; 65:501-507. [PMID: 35041797 DOI: 10.1044/2021_jslhr-21-00056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
PURPOSE Gender affirming voice training supports individuals as they explore and develop a healthy voice that feels congruent with their gender and sense of self. Although gender affirming voice training is increasingly available, there is no research comparing individual versus hybrid training outcomes in the existing literature. METHOD A retrospective chart review was performed on trans women and/or nonbinary individuals who attended either individual or hybrid (group and individual training) gender affirming voice and communication training at St. Michael's Hospital in Toronto between 2012 and 2019. Participant demographics, self-reported goal achievement, attendance, pre/post-Trans Woman Voice Questionnaire (TWVQ) scores, and pre/postspeaking fundamental frequency (SFF) were compared between individual and hybrid training participants. Multiple logistic regression analysis was performed to determine factors that could predict self-reported goal achievement. RESULTS Sixty-two trans women and/or nonbinary individuals who attended either individual (n = 43) or hybrid (n = 19) gender affirming voice and communication training were included in the study. Hybrid participants had a significantly higher goal achievement rate and therapy adherence rate compared with individual participants (74% vs. 21%; 84% vs. 28%, respectively). Both training models resulted in significant elevation of SFF and reduction of TWVQ scores. Inflection range did not change significantly for either training formats. Multiple logistic regression showed that hybrid training was a positive predictor for goal achievement (odds ratio = 2.2, 95% confidence interval [0.3, 4.1]). CONCLUSIONS Although clients in individual and hybrid gender affirming voice and communication training achieved significant pitch elevation and lower TWVQ scores, hybrid participants demonstrated significantly higher goal achievement and therapy adherence. This study suggests that hybrid training may provide a valuable support system that improves therapy success in this client population.
Collapse
|
39
|
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, de Tejada BM, Marzolini C, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rudin C, Schöni-Affolter F, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Weber R, Yerly S, van der Valk M, Geerlings SE, Goorhuis A, Hovius JW, Lempkes B, Nellen FJB, van der Poll T, Prins JM, Reiss P, van Vugt M, Wiersinga WJ, Wit FWMN, van Duinen M, van Eden J, Hazenberg A, van Hes AMH, Rajamanoharan S, Robinson T, Taylor B, Brewer C, Mayr C, Schmidt W, Speidel A, Strohbach F, Arastéh K, Cordes C, Pijnappel FJJ, Stündel M, Claus J, Baumgarten A, Carganico A, Ingiliz P, Dupke S, Freiwald M, Rausch M, Moll A, Schleehauf D, Smalhout SY, Hintsche B, Klausen G, Jessen H, Jessen A, Köppe S, Kreckel P, Schranz D, Fischer K, Schulbin H, Speer M, Weijsenfeld AM, Glaunsinger T, Wicke T, Bieniek B, Hillenbrand H, Schlote F, Lauenroth-Mai E, Schuler C, Schürmann D, Wesselmann H, Brockmeyer N, Jurriaans S, Gehring P, Schmalöer D, Hower M, Spornraft-Ragaller P, Häussinger D, Reuter S, Esser S, Markus R, Kreft B, Berzow D, Back NKT, Christl A, Meyer A, Plettenberg A, Stoehr A, Graefe K, Lorenzen T, Adam A, Schewe K, Weitner L, Fenske S, Zaaijer HL, Hansen S, Stellbrink HJ, Wiemer D, Hertling S, Schmidt R, Arbter P, Claus B, Galle P, Jäger H, Jä Gel-Guedes E, Berkhout B, Postel N, Fröschl M, Spinner C, Bogner J, Salzberger B, Schölmerich J, Audebert F, Marquardt T, Schaffert A, Schnaitmann E, Cornelissen MTE, Trein A, Frietsch B, Müller M, Ulmer A, Detering-Hübner B, Kern P, Schubert F, Dehn G, Schreiber M, Güler C, Schinkel CJ, Gunsenheimer-Bartmeyer B, Schmidt D, Meixenberger K, Bannert N, Wolthers KC, Peters EJG, van Agtmael MA, Autar RS, Bomers M, Sigaloff KCE, Heitmuller M, Laan LM, Ang CW, van Houdt R, Jonges M, Kuijpers TW, Pajkrt D, Scherpbier HJ, de Boer C, van der Plas A, van den Berge M, Stegeman A, Baas S, Hage de Looff L, Buiting A, Reuwer A, Veenemans J, Wintermans B, Pronk MJH, Ammerlaan HSM, van den Bersselaar DNJ, de Munnik ES, Deiman B, Jansz AR, Scharnhorst V, Tjhie J, Wegdam MCA, van Eeden A, Nellen J, Brokking W, Elsenburg LJM, Nobel H, van Kasteren MEE, Berrevoets MAH, Brouwer AE, Adams A, van Erve R, de Kruijf-van de Wiel BAFM, Keelan-Phaf S, van de Ven B, van der Ven B, Buiting AGM, Murck JL, de Vries-Sluijs TEMS, Bax HI, van Gorp ECM, de Jong-Peltenburg NC, de Mendonç A Melo M, van Nood E, Nouwen JL, Rijnders BJA, Rokx C, Schurink CAM, Slobbe L, Verbon A, Bassant N, van Beek JEA, Vriesde M, van Zonneveld LM, de Groot J, Boucher CAB, Koopmans MPG, van Kampen JJA, Fraaij PLA, van Rossum AMC, Vermont CL, van der Knaap LC, Visser E, Branger J, Douma RA, Cents-Bosma AS, Duijf-van de Ven CJHM, Schippers EF, van Nieuwkoop C, van Ijperen JM, Geilings J, van der Hut G, van Burgel ND, Leyten EMS, Gelinck LBS, Mollema F, Davids-Veldhuis S, Tearno C, Wildenbeest GS, Heikens E, Groeneveld PHP, Bouwhuis JW, Lammers AJJ, Kraan S, van Hulzen AGW, Kruiper MSM, van der Bliek GL, Bor PCJ, Debast SB, Wagenvoort GHJ, Kroon FP, de Boer MGJ, Jolink H, Lambregts MMC, Roukens AHE, Scheper H, Dorama W, van Holten N, Claas ECJ, Wessels E, den Hollander JG, El Moussaoui R, Pogany K, Brouwer CJ, Smit JV, Struik-Kalkman D, van Niekerk T, Pontesilli O, Lowe SH, Oude Lashof AML, Posthouwer D, van Wolfswinkel ME, Ackens RP, Burgers K, Schippers J, Weijenberg-Maes B, van Loo IHM, Havenith TRA, van Vonderen MGA, Kampschreur LM, Faber S, Steeman-Bouma R, Al Moujahid A, Kootstra GJ, Delsing CE, van der Burg-van de Plas M, Scheiberlich L, Kortmann W, van Twillert G, Renckens R, Ruiter-Pronk D, van Truijen-Oud FA, Cohen Stuart JWT, Jansen ER, Hoogewerf M, Rozemeijer W, van der Reijden WA, Sinnige JC, Brinkman K, van den Berk GEL, Blok WL, Lettinga KD, de Regt M, Schouten WEM, Stalenhoef JE, Veenstra J, Vrouenraets SME, Blaauw H, Geerders GF, Kleene MJ, Kok M, Knapen M, van der Meché IB, Mulder-Seeleman E, Toonen AJM, Wijnands S, Wttewaal E, Kwa D, van Crevel R, van Aerde K, Dofferhoff ASM, Henriet SSV, Ter Hofstede HJM, Hoogerwerf J, Keuter M, Richel O, Albers M, Grintjes-Huisman KJT, de Haan M, Marneef M, Strik-Albers R, Rahamat-Langendoen J, Stelma FF, Burger D, Gisolf EH, Hassing RJ, Claassen M, Ter Beest G, van Bentum PHM, Langebeek N, Tiemessen R, Swanink CMA, van Lelyveld SFL, Soetekouw R, van der Prijt LMM, van der Swaluw J, Bermon N, van der Reijden WA, Jansen R, Herpers BL, Veenendaal D, Verhagen DWM, Lauw FN, van Broekhuizen MC, van Wijk M, Bierman WFW, Bakker M, Kleinnijenhuis J, Kloeze E, Middel A, Postma DF, Schölvinck EH, Stienstra Y, Verhage AR, Wouthuyzen-Bakker M, Boonstra A, de Groot-de Jonge H, van der Meulen PA, de Weerd DA, Niesters HGM, van Leer-Buter CC, Knoester M, Hoepelman AIM, Arends JE, Barth RE, Bruns AHW, Ellerbroek PM, Mudrikova T, Oosterheert JJ, Schadd EM, van Welzen BJ, Aarsman K, Griffioen-van Santen BMG, de Kroon I, van Berkel M, van Rooijen CSAM, Schuurman R, Verduyn-Lunel F, Wensing AMJ, Bont LJ, Geelen SPM, Loeffen YGT, Wolfs TFW, Nauta N, Rooijakkers EOW, Holtsema H, Voigt R, van de Wetering D, Alberto A, van der Meer I, Rosingh A, Halaby T, Zaheri S, Boyd AC, Bezemer DO, van Sighem AI, Smit C, Hillebregt M, de Jong A, Woudstra T, Bergsma D, Meijering R, van de Sande L, Rutkens T, van der Vliet S, de Groot L, van den Akker M, Bakker Y, El Berkaoui A, Bezemer M, Brétin N, Djoechro E, Groters M, Kruijne E, Lelivelt KJ, Lodewijk C, Lucas E, Munjishvili L, Paling F, Peeck B, Ree C, Regtop R, Ruijs Y, Schoorl M, Schnörr P, Scheigrond A, Tuijn E, Veenenberg L, Visser KM, Witte EC, Ruijs Y, Van Frankenhuijsen M, Allegre T, Makhloufi D, Livrozet JM, Chiarello P, Godinot M, Brunel-Dalmas F, Gibert S, Trepo C, Peyramond D, Miailhes P, Koffi J, Thoirain V, Brochier C, Baudry T, Pailhes S, Lafeuillade A, Philip G, Hittinger G, Assi A, Lambry V, Rosenthal E, Naqvi A, Dunais B, Cua E, Pradier C, Durant J, Joulie A, Quinsat D, Tempesta S, Ravaux I, Martin IP, Faucher O, Cloarec N, Champagne H, Pichancourt G, Morlat P, Pistone T, Bonnet F, Mercie P, Faure I, Hessamfar M, Malvy D, Lacoste D, Pertusa MC, Vandenhende MA, Bernard N, Paccalin F, Martell C, Roger-Schmelz J, Receveur MC, Duffau P, Dondia D, Ribeiro E, Caltado S, Neau D, Dupont M, Dutronc H, Dauchy F, Cazanave C, Vareil MO, Wirth G, Le Puil S, Pellegrin JL, Raymond I, Viallard JF, Chaigne de Lalande S, Garipuy D, Delobel P, Obadia M, Cuzin L, Alvarez M, Biezunski N, Porte L, Massip P, Debard A, Balsarin F, Lagarrigue M, Prevoteau du Clary F, Aquilina C, Reynes J, Baillat V, Merle C, Lemoing V, Atoui N, Makinson A, Jacquet JM, Psomas C, Tramoni C, Aumaitre H, Saada M, Medus M, Malet M, Eden A, Neuville S, Ferreyra M, Sotto A, Barbuat C, Rouanet I, Leureillard D, Mauboussin JM, Lechiche C, Donsesco R, Cabie A, Abel S, Pierre-Francois S, Batala AS, Cerland C, Rangom C, Theresine N, Hoen B, Lamaury I, Fabre I, Schepers K, Curlier E, Ouissa R, Gaud C, Ricaud C, Rodet R, Wartel G, Sautron C, Beck-Wirth G, Michel C, Beck C, Halna JM, Kowalczyk J, Benomar M, Drobacheff-Thiebaut C, Chirouze C, Faucher JF, Parcelier F, Foltzer A, Haffner-Mauvais C, Hustache Mathieu M, Proust A, Piroth L, Chavanet P, Duong M, Buisson M, Waldner A, Mahy S, Gohier S, Croisier D, May T, Delestan M, Andre M, Zadeh MM, Martinot M, Rosolen B, Pachart A, Martha B, Jeunet N, Rey D, Cheneau C, Partisani M, Priester M, Bernard-Henry C, Batard ML, Fischer P, Berger JL, Kmiec I, Robineau O, Huleux T, Ajana F, Alcaraz I, Allienne C, Baclet V, Meybeck A, Valette M, Viget N, Aissi E, Biekre R, Cornavin P, Merrien D, Seghezzi JC, Machado M, Diab G, Raffi F, Bonnet B, Allavena C, Grossi O, Reliquet V, Billaud E, Brunet C, Bouchez S, Morineau-Le Houssine P, Sauser F, Boutoille D, Besnier M, Hue H, Hall N, Brosseau D, Souala F, Michelet C, Tattevin P, Arvieux C, Revest M, Leroy H, Chapplain JM, Dupont M, Fily F, Patra-Delo S, Lefeuvre C, Bernard L, Bastides F, Nau P, Verdon R, de la Blanchardiere A, Martin A, Feret P, Geffray L, Daniel C, Rohan J, Fialaire P, Chennebault JM, Rabier V, Abgueguen P, Rehaiem S, Luycx O, Niault M, Moreau P, Poinsignon Y, Goussef M, Mouton-Rioux V, Houlbert D, Alvarez-Huve S, Barbe F, Haret S, Perre P, Leantez-Nainville S, Esnault JL, Guimard T, Suaud I, Girard JJ, Simonet V, Debab Y, Schmit JL, Jacomet C, Weinberck P, Genet C, Pinet P, Ducroix S, Durox H, Denes É, Abraham B, Gourdon F, Antoniotti O, Molina JM, Ferret S, Lascoux-Combe C, Lafaurie M, Colin de Verdiere N, Ponscarme D, De Castro N, Aslan A, Rozenbaum W, Pintado C, Clavel F, Taulera O, Gatey C, Munier AL, Gazaigne S, Penot P, Conort G, Lerolle N, Leplatois A, Balausine S, Delgado J, Timsit J, Tabet M, Gerard L, Girard PM, Picard O, Tredup J, Bollens D, Valin N, Campa P, Bottero J, Lefebvre B, Tourneur M, Fonquernie L, Wemmert C, Lagneau JL, Yazdanpanah Y, Phung B, Pinto A, Vallois D, Cabras O, Louni F, Pialoux G, Lyavanc T, Berrebi V, Chas J, Lenagat S, Rami A, Diemer M, Parrinello M, Depond A, Salmon D, Guillevin L, Tahi T, Belarbi L, Loulergue P, Zak Dit Zbar O, Launay O, Silbermann B, Leport C, Alagna L, Pietri MP, Simon A, Bonmarchand M, Amirat N, Pichon F, Kirstetter M, Katlama C, Valantin MA, Tubiana R, Caby F, Schneider L, Ktorza N, Calin R, Merlet A, Ben Abdallah S, Weiss L, Buisson M, Batisse D, Karmochine M, Pavie J, Minozzi C, Jayle D, Castel P, Derouineau J, Kousignan P, Eliazevitch M, Pierre I, Collias L, Viard JP, Gilquin J, Sobel A, Slama L, Ghosn J, Hadacek B, Thu-Huyn N, Nait-Ighil L, Cros A, Maignan A, Duvivier C, Consigny PH, Lanternier F, Shoai-Tehrani M, Touam F, Jerbi S, Bodard L, Jung C, Goujard C, Quertainmont Y, Duracinsky M, Segeral O, Blanc A, Peretti D, Cheret A, Chantalat C, Dulucq MJ, Levy Y, Lelievre JD, Lascaux AS, Dumont C, Boue F, Chambrin V, Abgrall S, Kansau I, Raho-Moussa M, De Truchis P, Dinh A, Davido B, Marigot D, Berthe H, Devidas A, Chevojon P, Chabrol A, Agher N, Lemercier Y, Chaix F, Turpault I, Bouchaud O, Honore P, Rouveix E, Reimann E, Belan AG, Godin Collet C, Souak S, Mortier E, Bloch M, Simonpoli AM, Manceron V, Cahitte I, Hiraux E, Lafon E, Cordonnier F, Zeng AF, Zucman D, Majerholc C, Bornarel D, Uludag A, Gellen-Dautremer J, Lefort A, Bazin C, Daneluzzi V, Gerbe J, Jeantils V, Coupard M, Patey O, Bantsimba J, Delllion S, Paz PC, Cazenave B, Richier L, Garrait V, Delacroix I, Elharrar B, Vittecoq D, Bolliot C, Lepretre A, Genet P, Masse V, Perrone V, Boussard JL, Chardon P, Froguel E, Simon P, Tassi S, Avettand Fenoel V, Barin F, Bourgeois C, Cardon F, Chaix ML, Delfraissy JF, Essat A, Fischer H, Lecuroux C, Meyer L, Petrov-Sanchez V, Rouzioux C, Saez-Cirion A, Seng R, Kuldanek K, Mullaney S, Young C, Zucchetti A, Bevan MA, McKernan S, Wandolo E, Richardson C, Youssef E, Green P, Faulkner S, Faville R, Herman S, Care C, Blackman H, Bellenger K, Fairbrother K, Phillips A, Babiker A, Delpech V, Fidler S, Clarke M, Fox J, Gilson R, Goldberg D, Hawkins D, Johnson A, Johnson M, McLean K, Nastouli E, Post F, Kennedy N, Pritchard J, Andrady U, Rajda N, Donnelly C, McKernan S, Drake S, Gilleran G, White D, Ross J, Harding J, Faville R, Sweeney J, Flegg P, Toomer S, Wilding H, Woodward R, Dean G, Richardson C, Perry N, Gompels M, Jennings L, Bansaal D, Browing M, Connolly L, Stanley B, Estreich S, Magdy A, O'Mahony C, Fraser P, Jebakumar SPR, David L, Mette R, Summerfield H, Evans M, White C, Robertson R, Lean C, Morris S, Winter A, Faulkner S, Goorney B, Howard L, Fairley I, Stemp C, Short L, Gomez M, Young F, Roberts M, Green S, Sivakumar K, Minton J, Siminoni A, Calderwood J, Greenhough D, DeSouza C, Muthern L, Orkin C, Murphy S, Truvedi M, McLean K, Hawkins D, Higgs C, Moyes A, Antonucci S, McCormack S, Lynn W, Bevan M, Fox J, Teague A, Anderson J, Mguni S, Post F, Campbell L, Mazhude C, Russell H, Gilson R, Carrick G, Ainsworth J, Waters A, Byrne P, Johnson M, Fidler S, Kuldanek K, Mullaney S, Lawlor V, Melville R, Sukthankar A, Thorpe S, Murphy C, Wilkins E, Ahmad S, Green P, Tayal S, Ong E, Meaden J, Riddell L, Loay D, Peacock K, Blackman H, Harindra V, Saeed AM, Allen S, Natarajan U, Williams O, Lacey H, Care C, Bowman C, Herman S, Devendra SV, Wither J, Bridgwood A, Singh G, Bushby S, Kellock D, Young S, Rooney G, Snart B, Currie J, Fitzgerald M, Arumainayyagam J, Chandramani S. A highly virulent variant of HIV-1 circulating in the Netherlands. Science 2022; 375:540-545. [PMID: 35113714 DOI: 10.1126/science.abk1688] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
Collapse
|
40
|
Anderson J, Fatyga M, Schild S, Li J, Hu J. Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.10.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Michael Z, Kotamarti S, Arcot R, Morris K, Shah A, Anderson J, Armstrong A, Gupta R, Preminger G, Moul J, Oeffinger K, Shah K, Polascik T. Longitudinal outcomes following implementation of baseline PSA risk stratification of men in their forties. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00452-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Monshipouri M, Aliahmad B, Ogrin R, Elder K, Anderson J, Polus B, Kumar D. Thermal Imaging Potential and Limitations to Predict Healing of Venous Leg Ulcers. J Vasc Surg Venous Lymphat Disord 2022. [DOI: 10.1016/j.jvsv.2021.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Kabir F, Liu Z, Anderson J, Crossman D, Sasaki S, Huang L, Guo S, Guimbellot J, Rowe S, Harris W. 602: Antisense oligonucleotide target site blockade of miR-145 binding selectively enhances CFTR correction in airway epithelial cells and nasal organoids. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02025-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Fancher W, Patel R, CaJacob A, Anderson J. M037 SAFETY AND TOLERABILITY OF OMAZILUMAB IN A 4-YEAR-OLD ONCOLOGY PATIENT. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.211] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Anderson J, Hu J, Li J, Daniels T, Schild S, Fatyga M. Association Between Radiation Heart Dose and Overall Survival in Lung Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
46
|
Anderson J, Sheridan W, Desai B, Tomita D, Manning M. D005 CONSISTENTLY LOW HEREDITARY ANGIOEDEMA (HAE) ATTACK RATES OBSERVED IN US PATIENTS TREATED WITH BEROTRALSTAT. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
47
|
Guimbellot J, Ryan K, Anderson J, Liu Z, Natt J, Kersh L, Acosta E. 175: Epithelial cell pharmacokinetics of ivacaftor. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01600-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Kearney K, Anderson J, Cordina R, Lavender M, Celermajer D, Collins N, Dwyer N, Keating D, Williams T, Whitford H, Whyte K, Weintraub R, Keogh A, Kotlyar E, Lau EMT. Impact of left heart disease risk factors on risk stratification and treatment response in pulmonary arterial hypertension. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Contemporary registries have documented a change in the epidemiology of PAH patients displaying increasing co-morbidities associated with left heart disease (LHD). These patients are often excluded from randomized clinical trials. It is unclear whether the presence of LHD comorbidities may adversely impact the accuracy of risk stratification and response to PAH therapy.
Method
Data was extracted from the Pulmonary Hypertension Society of Australia and New Zealand registry for incident patients with a diagnosis with idiopathic/heritable/toxin-induced (I/H/D)-PAH and connective tissue disease (CTD) associated PAH from 2011 - 2020. Patients without available medication and follow up data were excluded. We used the AMBITION trial exclusion criteria to define the subpopulation with LHD risk factors and haemodynamic phenotype (PAH-rLHD).
Results
489 patients (I/H/D-PAH=251, CTD-PAH=238) were included in our analysis, with 103 (21.0%) fulfilling the definition of PAH-rLHD (34 had ≥3 risk factors for left heart disease (rLHD-hypertension, diabetes, obesity or ischaemic heart disease) and 76 had borderline haemodynamics (mean capillary wedge pressure 13–15 with pulmonary vascular resistance <500 dynes sec/cm5) including 7 who met both criteria). Compared to classical PAH, patients with PAH-rLHD were older at diagnosis (66±13 vs 58±19, p<0.001), had lower pulmonary vascular resistance (PVR: 393±266 vs 708±391, p=0.031) but worse exercise capacity (6MWD: 286±130m vs 327±136m, p=0.005). PAH-rLHD were more likely to be started on initial monotherapy, compared with “classical” PAH (73% vs 56%, p=0.002). In the monotherapy groups, endothelin receptor antagonists (ERA) were used in 73% PAH-rLHD, compared with 66% in classical PAH group. Both groups exhibited similar response to both mono- and combination therapy with commensurate improvements in WHO functional class (mean change 0.3±0.6 vs 0.3±0.8, p=0.443) and 6-minute walk distance (mean change 44±82 vs 48±101, p=0.723). There was no difference in survival between classical PAH and PAH-rLHD (log rank, p=0.29). The REVEAL 2.0 risk score effectively discriminated risk in both populations at baseline and first follow up (classical PAH: baseline C statistic 0.750, follow up 0.774 and PAH-rLHD: baseline C statistic 0.756, follow up 0.791).
Conclusion
Despite lower PVR at diagnosis, PAH-rLHD patients and “classical” PAH demonstrate similar response to first-line therapy with similar long term survival. The REVEAL 2.0 risk score can be effectively applied to the subpopulation of PAH-rLHD in real life clinical practice.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|
49
|
Wu V, Lo N, Lin RJ, Zirkle M, Anderson J, Lee JM. Admission of Patients With Obstructive Sleep Apnea Undergoing Ambulatory Surgery in Otolaryngology-Head and Neck Surgery. Ann Otol Rhinol Laryngol 2021; 131:941-945. [PMID: 34590890 PMCID: PMC9340133 DOI: 10.1177/00034894211048783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Objectives: Within Otolaryngology—Head and Neck Surgery (OHNS), obstructive sleep apnea (OSA) patients are frequently encountered. To implement policies and screening measures for admission of OSA patients undergoing ambulatory surgery, actual rates of admission must first be determined. We aimed to evaluate rates and reasons for admission of OSA patients after ambulatory OHNS surgery. Methods: Retrospective chart review was undertaken of all OSA patients undergoing elective day-surgery OHNS procedures at a tertiary center from January 1, 2018 to December 31, 2019. The primary outcome measure was percentage of OSA patients admitted to hospital after ambulatory OHNS surgery. Secondary outcome measures included reasons for admission. American Society of Anesthesiologists (ASA) score, perioperative complications, and patient demographics were captured. Results: There were 118 OSA patients, out of 1942 cases performed during the review period. Thirty-eight were excluded as the procedures were not considered ambulatory. The remaining 80 OSA patients were included for analysis, with an average age of 51.7, SD 13.8, and 30 (38%) females. The admission rate was 47.5% (38/80 patients). Admitted patients were older (P = .0061), and had higher ASA (P = .039). Indication for surgery or type of surgery did not differ among admitted and non-admitted patients. The majority of patients, 97% (37/38 patients), were admitted for post-operative monitoring. Conclusion: More than half of OSA patients did not require admission to hospital after ambulatory OHNS surgery, unaffected by indications for surgery or type of surgery. Higher ASA score and older age were found in admitted as compared to non-admitted patients.
Collapse
|
50
|
Sornasse T, Anderson J, Kato K, Lertratanakul A, Ritchlin CT, McInnes I. OP0030 TREATMENT OF NON-BIOLOGIC-DMARD-IR PSA PATIENTS WITH UPADACITINIB OR ADALIMUMAB RESULTS IN THE MODULATION OF DISTINCT FUNCTIONAL PATHWAYS: PROTEOMICS ANALYSIS OF THE SELECT-PSA 1 PHASE 3 STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms, psoriasis, physical function, fatigue, quality of life, and inhibited radiographic progression; improvements were observed as early as Week 2 (ACR20 and ACR50). UPA 15 mg QD was non-inferior to adalimumab (ADA) 40 mg EOW for ACR201Objectives:To determine the relative biological pathway modulation of UPA compared with ADA in patients with PsA via the evaluation of a pre-defined set of plasma proteins associated with inflammation.Methods:Patients from the SELECT-PsA1 study (DMARD-IR PsA patients) were randomly selected (PBO, n=100; UPA 15 mg QD, n=100; ADA 40 mg EOW, n = 100). The levels of 92 inflammation related protein biomarkers (pBM) were analyzed using a multiplexed Proximity Extension Assay platform in plasma samples collected at baseline, week 2, and 12; change from baseline in protein levels were expressed as Log2 Fold Change; a Repeated Measure Mixed Linear Model identified proteins modulated by UPA and ADA compared to Baseline. Functional pathway prediction was performed in silico with a commercially distributed software where 52 significantly modulated pBM (mean |Log2 FC| ≥ 0.1 AND FDR ≤ 0.05) were selected; results were summarized based on 3 core biological groups: 1) adaptive immune system, 2) innate immune system, and 3) non-immune connective and vascular systems.Results:At the single pBM-level, at the week 2 and 12 time points, treatment with UPA 15 mg QD resulted in distinct down modulation of T cell-associated (CD5, CD8a, IL15Ra, SLAMF1, TRANCE) and myeloid cell-associated pBM (CSF-1, CCL7, CCL13) that was not observed in the ADA treated group. Reciprocally, treatment with ADA 40 mg EOW resulted in a specific down modulation of a subset of neutrophil associated pBM (CCL3, CCL4, and S100A12). Both treatments resulted in the down modulation of IFN-, IL6-, and TNF-related pBM (CXCL9, CXCL10, CXCL11, IL6, TNFRSF19, and TNSF14) suggesting a common node of activity related to these pivotal cytokine-signaling pathways.Functional pathway prediction based on the pBM data revealed that treatment with UPA is preferentially associated with the inhibition of T cells, but also NK cells and lymphocytes, compared to the predicted effects of treatment with ADA. Treatment with UPA also preferentially inhibited pathways related to bone damage and angiogenesis, as compared to the predicted effect of treatment with ADA. Finally, both treatments were predicted to inhibit multiple pathways associated with the activity of myeloid cells and phagocytes.Conclusion:Consistent with previous observations in RA2, UPA is predicted to inhibit multiple functional pathways associated the pathobiology of PsA belonging to the general categories of adaptive and innate immunity but also non-immune vascular and connective tissue biology. In contrast, treatment with ADA appears to affect more specifically functional pathways associated with the innate immune system.References:[1]McInnes, I. et al. Annals of the Rheumatic Diseases 79, 16-17 (2020).[2]Sornasse, T., Song, I.H., Radstake, T. & McInnes, I. Annals of the Rheumatic Diseases 79, 581-582 (2020).Acknowledgements:AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.Disclosure of Interests:Thierry Sornasse Shareholder of: AbbVie, Employee of: AbbVie, Jaclyn Anderson Shareholder of: AbbVie, Employee of: AbbVie, Koji Kato Shareholder of: AbbVie, Employee of: AbbVie, Apinya Lertratanakul Shareholder of: AbbVie, Employee of: AbbVie, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, Grant/research support from: AbbVie, Amgen, UCB, Iain McInnes Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, UCB Pharma, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, UCB Pharma
Collapse
|